Abstract
Tumour markers correlate strongly with prognosis based on tumour burden and surgical resectability. If chemotherapy is extremely effective in certain stage of the disease, the sensitive marker may be of great use in monitoring disease response and drug treatment. Hence, this study was launched to evaluate the changes in tumour marker enzymes like lactate dehydrogenase (LDH), glumate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT), alkaline phosphatase, and acid phosphatase in before and after 3 and 6 months tamoxifen treated breast cancer patients. In addition, the changes in serum glycoproteins viz., hexose, hexosamine, and sialic acid and lysosomal enzymes such as N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were analysed in these patients. These values were compared with their age matched healthy control subjects. At 6 months evaluation, the tamoxifen treated postmenopausal breast cancer women showed a statistically significant decreased (p < 0.001, 0.05 respectively) levels of LDH, SGOT, SGPT, alkaline and acid phosphatases than their baseline values. Similarly, the levels of hexose, hexosamine, and sialic acid and N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were decreased significantly (p < 0.001 ) in tamoxifen received postmenopausal women. The result of this study suggested that tamoxifen potentially retard the metastasis of breast cancer as well as the bone demineralisation in postmenopausal breast cancer women. Thus, tamoxifen may also have its antitumour activity through its beneficial effects on tumour marker enzymes and serum proteins in breast cancer women.
Similar content being viewed by others
References
Jordan VC: A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110: 507–517, 1993
Jordan VC: Overview from the international conference on long term tamoxifen therapy for breast cancer. J Natl Cancer Inst 84: 231–234, 1992
Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659–663, 1994
Dristrian AM, Schwartz MK, Greenberg EJ, et al.: Effect of tamoxifen on serum cholesterol and lipoproteins during chemotherapy. Clin Chim Acta 223: 43–52, 1993
McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial. Br Med J 303: 435–437, 1991
Bruning PF, Bonfrer JMG, Hart AAM, et al.: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58: 497–499, 1988
Love RR, Mazess RB, Barden HS, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992
Lemer LJ, Jordan VC: Development of antiestrogen and their use in breast cancer. Cancer Res 50: 4177–4189, 1990
Coezy EJ, Borgama L, Ruchefort M: Tamoxifen and metabolises in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317–321, 1982
Reddel RR, Murphy LC, Hall RE, Sutherland RL: Differential sensitivity of human breast cancer cell line to the growth-inhibitory effects of tamoxifen. Cancer Res 45: 1525–1531, 1985
O'Brain CA, Liskam RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462–2465, 1985
Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiestrase. Biochim Biophys Res Commun 118: 27–32, 1984
Thangaraju M: Biochemical studies on the antitumour activity of tamoxifen in breast cancer women with special reference to plasma lipids and lipid peroxides. PhD thesis, University of Madras, India 171–173, 1995
Schwartz MK: Enzymes as prognostic markers and therapeutic indicator in patients with cancer. Clini Chimi Acta 206: 77–82, 1992
Nachbar MS, Oppenheim JD, Aull F: Cell surface contributions to the malignant process. Am J Med Sci 268: 122–138, 1974
Pederson PL: Enzymology ultrastructure and energies of mitochondria from three morris hepatoma of widely differentiated growth rates. Gann Monograph on Cancer Res 13: 251–165, 1972
Buck CA, Fuhrer JP, Soslan G: Membrane glycoproteins sub-cellular fractions of control and virus transformer cells. J Biol Chem 249: 1541–1550, 1974
Bossmann HB, Hall TC: Enzyme activity in invasive tumours of human breast and colon. Proc Natl Acad Sci, USA 71: 1833–1837, 1974
Bossmann HB, Lockwood T, Morgan HR: Surface biochemical changes accompanying primary infection with Rous Sarcoma Virus II. Proteolytic and glycosidase activity and sublethal autolysis. Exp Cell Res 83: 25–30, 1974
Roth S, McGuire EJ, Rosemann S: Evidence for cell surface glycosyltransferases: their potential role in cellular recognition. J Biol Chem 51: 536–547, 1971
Bossmann HB: Glycoprotein degradation: Glycosidases in fibroblasts transformed by oncogenic virus. Exp Cell Res 54: 217–221, 1969
Ilanchezhian S, Thangaraju M, Sachdanandam P: Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. Cancer Biochem Biophys 15: 1–8, 1995
Thangaraju M, Vijayalakshmi T, Sachdanandam P: Effect of tamoxifen on lipid peroxide and antioxidative system in postmenopausal women with breast cancer. Cancer 73: 659–663, 1995
Thangaraju M, Ilanchezhian S, Ezhilarasi R, Sachdanandam P: Lipid peroxidation and antioxidant enzyme levels in tamoxifen-treated breast cancer women in relation to the menopausal status of the patients. Med Sci Res 21: 721–724, 1993
Thangaraju M, Ezhilarasi R, Sachdanandam P: Effect of tamoxifen on erythrocyte membrane lipids, lipid peroxides and antioxidative enzymes in breast cancer women. Cancer Biochem Biophy 14: 297–302, 1995
Dubowski KM: An O-toluidine method for body fluid glucose determinations. Clin Chem 8: 215–235, 1962
Sasaki T, Matsuis S: Effect of acetic acid concentration on the colour reaction in the O-toluidine-boric acid method of the blood glucose determination. Rinsho-Kagaku 1: 346–353, 1972
Drabkin DL, Austin JN: Spectrophotometric studies, spectrophotometric constants for common haemoglobin derivatives in human, dog, and rabbit blood. J Biol Chem 98: 719–733, 1932
Lowry OH, Rosebrough NJ, Farr AL, Randall R: Protein measurement with Folin's phenol reagent. J Biol Chem 193: 265–275, 1952
King F: Colorimetric determination of serum enzymes. In: Practical Clinical Enzymology. Van Nostrand, London 1: 247–283, 1952
Moog F: Acid and alkaline phosphatases in chick embryo. J Cell Comp Physiol 28: 197–208, 1946
Tettamanti G, Banali F, Marchesini S, Zambothi Y: A new procedure for the extraction, purification, and fractionation of brain gangliosides. Biochem Biophys Acta 267: 160–170, 1983
Niebes P: Determination of enzyme and degradation products of GAG metabolism in the serum of healthy and various subjects. Clin Chim Acta 42: 399–408, 1972
Wagner WD: More sensitive assay discriminating galactosamine and glucosamine in mixtures. Anal biochem 94: 394–397, 1979
Warren L: The thiobarbituric acid assay of sialic acid. J Biol Chem 234: 1971–1975, 1959
Hultberg B, Lindsten J, Siobtad S: Molecular forms and activities of glycosidases in amniotic fluid cells. Biochem J 155: 599–605, 1976
Meisler MH, Fry JB, Palyan K: Beta-galactosidase from human liver. Fed Proc Fed Ame Soc Exp Biol 30: 1118–1121, 1971
Kawaii Y, Anno K: Mucopolysaccharide degrading enzymes from the liver of the squill. Ommastrephes Sloanifacifieus. Biochem Biophys Acta 242: 428–436, 1971
Greengard O, Head JF, Goldenberg SL, Krishchem PA: Enzyme pathology and the histologic categorisation of human lung tumours. The continue qualitative biochemical indices of neoplasticity. Cancer 49: 46–48, 1982
Hilt R, Fledsten ML, Gibson SL, Savio ED: A logistic model based enzyme activities for the prediction of response of breast cancer patients to chemotherapy. Cancer 50: 1734–1738, 1982
Schwartz MK: Enzymes in cancer. Clin Chem 19: 10–22, 1973
Pui CH, Dodge PK, Dahl GV, et al.: Serum lactic dehydrogenase levels has prognostic value in childhood acute lymphoblastic leukemia. Blood 66: 778–782, 1985
Ferraris AM, Giuntini P, Gaetani GF: Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54: 928–932, 1979
Finck S, Giuliano AK, Morton DL: LDH and melanoma. Cancer 51: 840–843, 1983
Neville AM: Prognostic factors and primary breast cancer. Diag Oncol 1: 5363, 1991
Khan N, Tyagi SP, Salahuddain A: Diagnostic and prognostic significance of serum cholin-estrase and lactate dehydrogenase in breast cancer. Ind J Pathol Microbiol 34: 126–130, 1991
Kumar K: Plasma lipid alteration and related biochemical studies in mammary tumour. PhD Thesis, University of Madras, India. 1991, pp 127–135
Nano R, Roveta G, Rezzani R, Roadella L: Changes observed in lactate dehydro genase activity in fibro sarcoma bearing rats. Boll Soc Ital Sper 65: 273–278, 1989
Hisson JR, Bowden RT, Moore MR: Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D. Endocrinol 125: 418–423, 1989
Nagai MA, Sonohara S, Brentani MM: Estrogen control of lactate dehydrogenase isoenzyme-5 in human breast cancer. Int J Cancer 41: 10–16, 1988
Tsai CL, Liu TK: Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sciences 50: 1943–1951, 1992
Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res Treat 3: 573–586, 1983
Coleman RE, Rubens RD: Bone metastases and breast cancer. Cancer Treat Rev 12: 251–270, 1985
Gutman AB, Gutman EB: An acid phosphatase occuring in the serum of patients with metastasizing carcinoma of the prostatic gland. J Clin Invest 17: 473–478, 1938
Nguyen M, Bonneterre J, Hecquet B, et al.: Plasma acid and alkaline phosphatase in patients with breast cancer. Anticancer Res 11: 831–834, 1991
Desoize B, Veiler V, Pourny C, et al.: Isoenzymes of alkaline and acid phosphatases as bone metastasis marker in breast cancer patients. Anticancer Res 9: 1105–1110, 1989
DiLovenzo D, Gianni M, Savoldi GF, et al.: Progesterone induced the expression of alkaline phosphastase is associated with a secretory phenotype in T47D breast cancer cells. Biochem Biophys Res Comuni 192: 1066–1972, 1993
Love RR, Mazess RB, Barden HS, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992
Kapiler M: Cell surface shedding. The phenomenon with a possible significance. J Theor Biol 62: 253–261, 1976
Yogeswaran G: Cell surface glycolipids in malignant transformation. Adv Cancer Res 38: 289–350, 1983
Burridge K: Changes in cellular glycoproteins after transformation. Proc Natl Acad Sci 73: 4457–4461, 1976
Pearson JP, Pretlow TP, Bradlay EL, et al.: Beta-glucuronidase activity in prostatic carcinoma and benign prostatic hyperplasia. Cancer 64: 911–915, 1989
Bossmann HB, Bieber GF, Brown A, et al.: Biochemical parameters correlated with tumour cell implantation. Nature 246: 487–489, 1973
Severini G, Diana L, Giovannandrea RD, Tirelli C: A study of serum glycosideases in cancer. J Cancer Res Clin Oncol 121: 61–63, 1995
Adamo V, Altavilla G, Caristi M, et al.: Serum sialic acid are tumour marker in neoplastic disease. Mineral Med 76: 2067–2074, 1985
Potter VR: Biochemical perspectives in cancer research. Cancer Res 24: 1085–1098, 1964
Toimela T, Tahti H, Salminen L: Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophtha Res 27: 150–153, 1995
Gotterdesen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853–857, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thangaraju, M., Rameshbabu, J., Vasavi, H. et al. The salubrious effect of tamaxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer women. Mol Cell Biochem 185, 85–94 (1998). https://doi.org/10.1023/A:1006874005764
Issue Date:
DOI: https://doi.org/10.1023/A:1006874005764